How Much Does Breztri Aerosphere Cost With Medicare?
Breztri Aerosphere (Budesonide/Glycopyrrolate/Formoterol) costs an average of $305 per Medicare Part D claim, with total Medicare spending of $756.0M in the latest year. No generic alternative is currently available.
Key Facts: Breztri Aerosphere Cost
- Medicare Part D avg
- $305/claim
- Likely Part D tier
- Tier 3 (non-preferred brand)
- Annual cost/patient
- $2,191
- Generic available
- No
- Manufacturer
- AstraZeneca
- Treats
- Asthma/COPD
- Patent expires
- 2031-07-24
- YoY price change
- +48.3%
Source: CMS Medicare Part D Spending Dashboard. Tier placement inferred from typical formulary norms — confirm with your specific Part D plan.
Breztri Aerosphere Medicare Coverage & Out-of-Pocket Cost
Breztri Aerosphere is covered under Medicare Part D, with the program paying an average of $305 per prescription fill. Breztri Aerosphere typically falls on Tier 3 (non-preferred brand) of standard Part D formularies. Typical copay: $40-$100 per fill, depending on plan formulary.
Your actual out-of-pocket cost depends on three factors: (1) formulary tier — your plan's specific placement; (2) deductible status — most plans require you to meet up to a $590 deductible (2025) before copays kick in; (3) coverage phase — initial coverage, then the donut hole was eliminated in 2025, replaced by a hard $2,000 annual out-of-pocket cap under the Inflation Reduction Act. Once you hit $2,000 in true out-of-pocket spending, the rest of your Part D drugs are free for the year.
No generic is currently available for Breztri Aerosphere. Medicare beneficiaries cannot use manufacturer copay cards (anti-kickback statute prohibits them for federal program enrollees), but charity foundations such as the PAN Foundation, NeedyMeds, and the HealthWell Foundation offer copay grants for many asthma/copd drugs. The Medicare Extra Help (LIS) program also reduces Part D costs to near-zero for income-qualified beneficiaries (under 150% of the federal poverty level).
For cash-pay or commercial insurance scenarios, compare prices using GoodRx, SingleCare, or Cost Plus Drugs before filling — discount-program prices sometimes beat Part D copays for lower-cost generics.
Breztri Aerosphere is manufactured by AstraZeneca and prescribed primarily for Asthma/COPD. In the most recent Medicare Part D data, 2,480,000 claims were filed for 345,000 unique beneficiaries, at an average cost of $305 per claim. Average annual cost per beneficiary is $2,191.
Year over year, Medicare spending on Breztri Aerosphere has increased by +48.3%. No generic substitute is available, so the brand-name price reflects the full market cost. Its patent expires 2031-07-24.
Breztri Aerosphere belongs to the Asthma & COPD Inhalers class. Inhaled corticosteroids (ICS) reduce airway inflammation. Long-acting beta-agonists (LABA) relax airway muscles for 12-24 hours. Long-acting muscarinic antagonists (LAMA) block bronchoconstriction. Triple combination inhalers (Trelegy) combine ICS + LABA + LAMA. Biologics (Nucala, Xolair, Dupixent) target specific immune pathways in severe asthma that doesn't respond to inhalers alone.
Key Data
| Metric | Value |
|---|---|
| Avg Cost Per Claim | $305 |
| Total Medicare Spending | $756.0M |
| Total Claims | 2,480,000 |
| Beneficiaries | 345,000 |
| Generic Available | No |
| Year-Over-Year Change | +48.3% |
Other Drugs for Asthma/COPD
Frequently Asked Questions
Medicare Part D pays an average of $305 per claim for Breztri Aerosphere. Breztri Aerosphere is typically placed on Tier 3 (non-preferred brand) of standard Part D formularies. Typical copay: $40-$100 per fill, depending on plan formulary. As of 2025, total annual out-of-pocket on Part D is capped at $2,000 under the Inflation Reduction Act.
Yes. Breztri Aerosphere appears in Medicare Part D claims data, with 345,000 beneficiaries filling 2,480,000 prescriptions in the latest year. Specific coverage depends on your plan's formulary — call the number on your insurance card or check the plan's Summary of Benefits to confirm prior authorization, step therapy, or quantity limit requirements.
Breztri Aerosphere (Budesonide/Glycopyrrolate/Formoterol) costs an average of $305 per Medicare Part D claim, with total Medicare spending of $756.0M in the latest year. No generic alternative is currently available.
No. As of the latest FDA Orange Book data, there is no generic version of Breztri Aerosphere (Budesonide/Glycopyrrolate/Formoterol). Patent protection extends until 2031-07-24, after which generics may enter the market.
Medicare beneficiaries cannot use manufacturer copay cards (anti-kickback statute), but several options exist: (1) Apply to charity copay foundations like the PAN Foundation, NeedyMeds, HealthWell Foundation, or Patient Advocate Foundation — many cover asthma/copd drugs; (2) Ask your prescriber about therapeutic alternatives in the same drug class that may be on a lower tier; (3) For some drugs, paying cash via GoodRx or Cost Plus Drugs can beat your Medicare copay — always compare before filling; (4) If your income is below 150% of the federal poverty level, you may qualify for the Medicare Extra Help (Low-Income Subsidy) program, which reduces Part D costs to near-zero.
Breztri Aerosphere is manufactured by AstraZeneca. The FDA application number is NDA212122.
Breztri Aerosphere (Budesonide/Glycopyrrolate/Formoterol) is primarily prescribed for Asthma/COPD.
Medicare Part D spending on Breztri Aerosphere has increased +48.3% year over year. Total program spending reached $756.0M in the latest reporting year.
Breztri Aerosphere (Budesonide/Glycopyrrolate/Formoterol) costs an average of $305 per Medicare Part D claim, with total Medicare spending of $756.0M in the latest year. No generic alternative is currently available.
This answer pulls from CMS Medicare Part D Drug Spending data, the authoritative federal source for U.S. Medicare prescription-drug pricing. The headline number above is the direct answer; what follows is the additional context most readers need to use the answer for a real decision rather than just a fact lookup.
A practical caveat: the headline answer above reflects the most recent CMS Medicare Part D Drug Spending data vintage; underlying data is often revised for months after first publication, and the right reference for any specific decision is whichever vintage is current at the time of the decision. The as-of date is stamped on every page.
Source: CMS Medicare Part D Spending, 2026.